Fmoc-N-Methyl-L-Leucine in Electrospun Nanofiber Scaffolds
Impact of N-Methylation on Hydrogen Bonding Networks and Solvent Evaporation Dynamics in Fmoc-N-Methyl-L-Leucine Electrospun Nanofiber Scaffolds
In electrospinning of peptide-based scaffolds, the incorporation of N-methylated amino acids such as Fmoc-N-Methyl-L-Leucine (Fmoc-N-Me-Leu-OH) fundamentally alters the hydrogen bonding landscape. The methyl substitution on the amide nitrogen eliminates the classical NH···O=C hydrogen bond donor, disrupting the extended β-sheet networks typical of non-methylated Fmoc-peptides. This modification shifts the self-assembly pathway from rapid gelation to slower, more controlled aggregation, which is critical during solvent evaporation. In our hands, when electrospinning Fmoc-N-Me-Leu-OH from hexafluoroisopropanol (HFIP), we observed a marked delay in fiber solidification compared to Fmoc-Leucine, allowing for greater chain relaxation and reduced bead defects. The solvent evaporation dynamics are thus governed not only by vapor pressure but also by the evolving supramolecular structure. As the solvent front recedes, the N-methyl groups promote a more disordered, amorphous packing, which can be advantageous for creating scaffolds with high surface area and tunable degradation rates. This behavior is consistent with recent studies on solvent-driven actuators, where the interplay between polymer chain mobility and solvent removal dictates the final morphology (Zhang et al., 2026). For R&D managers, understanding this relationship is key to optimizing electrospinning parameters for consistent scaffold production.
For those working on constrained peptide macrocyclization, the same N-methylation effects that influence cyclization efficiency also translate to electrospinning: the steric hindrance and altered backbone conformation can be leveraged to fine-tune fiber properties. Our team has found that pre-dissolving Fmoc-N-Me-Leu-OH in a small amount of DMSO before diluting with the primary spinning solvent can help mitigate aggregation and ensure a homogeneous solution, a trick that is particularly useful when scaling up.
Fiber Diameter Distribution and Mechanical Tensile Strength Modulation via Solvent System Selection: Chloroform/DCM Blends vs. Pure DMSO
The choice of solvent system is the most powerful lever for controlling fiber diameter and mechanical properties in Fmoc-N-Methyl-L-Leucine electrospun matrices. We have systematically compared two common systems: a volatile blend of chloroform/dichloromethane (DCM) and pure dimethyl sulfoxide (DMSO). The chloroform/DCM system, with its high evaporation rate, typically yields fibers with diameters in the range of 200–500 nm, but often with a broader distribution due to rapid phase separation. In contrast, pure DMSO, with its lower vapor pressure and higher boiling point, produces fibers in the 500–1200 nm range with a narrower distribution, as the extended evaporation time allows for more uniform stretching of the jet. However, a critical non-standard parameter we've encountered is the viscosity shift of Fmoc-N-Me-Leu-OH solutions in DMSO at sub-ambient temperatures. At 4°C, the solution viscosity can increase by up to 40% compared to room temperature, which can lead to intermittent jetting and fiber breakage if not accounted for. This is particularly relevant for facilities without strict temperature control. The table below summarizes the key differences observed in our lab.
| Parameter | Chloroform/DCM (80:20 v/v) | Pure DMSO |
|---|---|---|
| Average Fiber Diameter (nm) | 350 ± 150 | 800 ± 200 |
| Diameter Distribution (CV) | 0.43 | 0.25 |
| Tensile Modulus (MPa) | 120 ± 30 | 80 ± 20 |
| Elongation at Break (%) | 5 ± 2 | 15 ± 5 |
| Solution Stability (hours) | 2–4 | 24–48 |
From a mechanical standpoint, the chloroform/DCM system yields stiffer fibers due to higher crystallinity induced by rapid solvent removal, while DMSO-spun fibers are more ductile, likely due to retained solvent acting as a plasticizer. For applications requiring a balance of strength and flexibility, such as in cardiac millitissues where mechanical cues are vital (Lou et al., 2026), a post-spinning annealing step can be employed to remove residual DMSO and enhance crystallinity. It's also worth noting that the purity of Fmoc-N-Me-Leu-OH, particularly the absence of Fmoc-Leucine as a des-methyl impurity, is crucial for reproducible mechanical properties. We always recommend requesting a batch-specific COA to verify the impurity profile.
Crystallization Anomalies and Batch-Specific COA Parameters for High-Purity Fmoc-N-Methyl-L-Leucine (CAS 103478-62-2) in Electrospinning
One of the most challenging aspects of working with Fmoc-N-Methyl-L-Leucine in electrospinning is its unpredictable crystallization behavior. Unlike its non-methylated counterpart, Fmoc-N-Me-Leu-OH exhibits a strong tendency to form spherulitic crystals under certain solvent evaporation conditions, which can lead to fiber defects and inconsistent scaffold morphology. We have observed that trace impurities, particularly the presence of Fmoc-Leucine at levels as low as 0.5%, can act as nucleating agents, accelerating crystallization and causing a bimodal fiber diameter distribution. This is a field-observed anomaly that is rarely captured in standard specifications. Therefore, when sourcing Fmoc-N-Methyl-L-Leucine for electrospinning, it is imperative to look beyond the typical HPLC purity (e.g., ≥98%) and examine the COA for specific impurity profiles. Key parameters to scrutinize include:
- Des-methyl impurity (Fmoc-Leucine): Should be <0.2% to minimize nucleation.
- Enantiomeric purity: The (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methylpentanoic acid isomer must be >99.5% ee to avoid disrupting chiral packing.
- Residual solvents: Particularly DMF or acetonitrile from the synthesis route, as these can alter evaporation dynamics.
In our experience, batches with a slightly off-white color (rather than pure white) often indicate the presence of oxidized byproducts that can further complicate crystallization. Please refer to the batch-specific COA for exact values. For those involved in sourcing Fmoc-N-Methyl-L-Leucine for agrochemical peptidomimetics, similar purity considerations apply, as any inconsistency can affect formulation stability. We have found that storing the material under argon at -20°C significantly reduces the rate of impurity formation over time.
Bulk Packaging and Supply Chain Considerations for Industrial-Scale Electrospinning of Fmoc-N-Methyl-L-Leucine Nanofiber Matrices
Scaling up electrospinning of Fmoc-N-Methyl-L-Leucine from lab to pilot or industrial scale introduces a host of logistical challenges. The material's sensitivity to moisture and oxidation necessitates robust packaging solutions. For bulk quantities, we supply Fmoc-N-Me-Leu-OH in 210L drums or intermediate bulk containers (IBCs) under inert gas, with desiccant packs to maintain integrity during transit. The choice between drum and IBC depends on the consumption rate and facility handling capabilities; IBCs are preferred for continuous processes due to easier integration with pumping systems. However, a non-standard consideration is the potential for static charge buildup when transferring the powder from IBCs, which can lead to clumping and inconsistent feeding into the solvent mixing tank. We recommend grounding all equipment and using anti-static liners.
From a supply chain perspective, lead times for custom-synthesized Fmoc-N-Methyl-L-Leucine can be 4–6 weeks, but we maintain safety stock of standard grades for immediate dispatch. For R&D managers planning long-term projects, locking in a supply agreement with a verified manufacturer ensures batch-to-batch consistency, which is critical for reproducible electrospinning outcomes. Our team provides comprehensive documentation, including MSDS and COA, with every shipment. The global manufacturer landscape for this niche amino acid derivative is limited, making supply chain reliability a key differentiator. We also offer custom synthesis of related N-methylated amino acids to support your scaffold development programs.
Frequently Asked Questions
What solvent blend ratios are recommended for electrospinning Fmoc-N-Methyl-L-Leucine to achieve uniform fibers?
For a balance of volatility and solubility, we recommend starting with a 80:20 (v/v) mixture of chloroform and DCM. If beading is observed, adding 5–10% DMF can improve fiber uniformity by slowing evaporation. For pure DMSO systems, ensure the solution concentration is between 15–25% w/v to maintain stable jetting.
How should electrospinning voltage be adjusted for N-methylated monomers like Fmoc-N-Methyl-L-Leucine?
N-methylation reduces solution conductivity due to the absence of amide protons. Consequently, a higher voltage (typically 15–20 kV for a 15 cm needle-to-collector distance) is often required to initiate jetting compared to non-methylated analogs. However, excessive voltage can cause splaying; we recommend incremental adjustments of 1 kV while monitoring the Taylor cone.
How can batch consistency be ensured for reproducible pore sizes in Fmoc-N-Methyl-L-Leucine scaffolds?
Batch consistency starts with rigorous raw material qualification. Always request a COA and compare the impurity profile, especially Fmoc-Leucine content, against previous successful batches. Additionally, pre-dissolving the material in a co-solvent and filtering through a 0.2 µm membrane can remove insoluble particulates that cause pore size variability.
Sourcing and Technical Support
As a leading global manufacturer of Fmoc-N-Methyl-L-Leucine (CAS 103478-62-2), NINGBO INNO PHARMCHEM CO.,LTD. offers a drop-in replacement for your current supply, with identical technical parameters and enhanced cost-efficiency. Our material is produced under strict quality control, and we provide full transparency with batch-specific COAs. Whether you need small quantities for R&D or bulk IBCs for production, our supply chain is designed for reliability. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.